Welcome to our dedicated page for Spruce Biosciences SEC filings (Ticker: SPRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Spruce Biosciences filings document the regulatory, financing and governance record of a late-stage biopharmaceutical company developing TA-ERT for Sanfilippo Syndrome Type B (MPS IIIB). Form 8-K disclosures cover material agreements, including loan and security arrangements, at-the-market equity sale agreements, collaboration and license matters, and furnished clinical data updates related to the TA-ERT program.
Proxy materials describe shareholder voting matters, director elections, board committee changes, executive compensation and equity incentive plan matters. The filing record also includes capital-structure disclosures tied to common stock, equity awards, financing arrangements, risk factors and public-company governance.
Parkman Healthcare Partners LLC filed an initial Form 3 disclosing indirect ownership of 1,051 shares of Spruce Biosciences, Inc. (SPRB) held through private fund investments. The filing, tied to an event on 10/06/2025, lists the reporting person as a director and notes the reported holdings reflect only the reporting person's pecuniary interest rather than an admission of beneficial ownership. A separate Form 3 will follow for Gregory Martinez once CIK codes are available.
Spruce Biosciences, Inc. entered into a private placement with institutional investors, agreeing to sell 502,181 shares of common stock and pre-funded warrants to purchase up to 233,144 additional shares at a purchase price of $68.00 per share, for expected gross proceeds of approximately $50.0 million at closing. The pre-funded warrants have a $0.01 per share exercise price, are exercisable for five years, and include ownership limits that generally cap each holder below specified percentages of outstanding common stock. Spruce plans to file resale registration statements for the shares and warrant shares after closing and intends to use its strengthened capital position to advance tralesinidase alfa enzyme replacement therapy toward a planned biologics license application in the first quarter of 2026 and a potential U.S. commercial launch in late 2026.
Spruce Biosciences Inc. received a joint Schedule 13G reporting that Ikarian Capital, LLC and Neil Shahrestani disclose beneficial ownership of 121,356 shares of the company's common stock, representing 21.6% of the outstanding class based on August 12, 2025 share count of 563,042 shares. The shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts for which Ikarian Capital acts as adviser; Mr. Shahrestani is identified as sole manager of Ikarian Capital and is described as indirectly controlling Ikarian Capital. The filing states the holdings were acquired in the ordinary course of business and are not intended to influence control.